Clascoterone is under clinical development by Cosmo Pharmaceuticals and currently in Phase I for Colon Cancer. According to GlobalData, Phase I drugs for Colon Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Clascoterone LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Clascoterone overview
Cosmo Pharmaceuticals overview
Cosmo Pharmaceuticals (Cosmo) develops drugs for the treatment of gastrointestinal diseases and dermatology. It develops pharmaceutical products based on its multi-matrix technology. The company offers products such as Lialda, Mezavant, Mesavancol and Uceris for the treatment of ulcerative colitis. It also offers Eleview which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures. The company’s manufacturing facility is located in Lainate, Milan. Cosmo is headquartered in Dublin, Ireland.
For a complete picture of Clascoterone’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.